T&CT is pleased to announce that its close relationship with Hairclone Ltd is continuing to strengthen with the announcement that both companies are now collaborating on a number of new R&D initiatives using T&CT’s proprietary technology in the fields of adipose and tissue handling, as well as Adipose derived Stem Cells (ADRC’s), to further explore promising work undertaken by Hairclone. The potential for the use of either autologous or allogeneic ADRC’s as basis for either clinical products or topical solutions has recently been independently highlighted by a new study from a highly respected team in South Korea. T&CT’s contribution to the research is critical, as handling and storage of the human samples, is the basis on which all IP will be developed. Hairclone already has a long-standing relationship with T&CT i which T&CT provides various services to Hairclone proving that T&CT’s deep competence & capabilities in Adipose handling & processing are likely to be a strong platform for future commercial development in the future.
Tissue & Cell Technologies
Rebuilding following breast cancer treatment
